Anti-Human IL-17A (Secukinumab)

Humanized antibody derived from mouse clone 2321

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Secukinumab. Secukinumab activity is directed against IL-17A.

IL-17 is a group of proinflammatory cytokines (IL-17A to IL-17F) released by T helper 17 (Th17) cells¹. IL-17A is the key effector cytokine of the group¹ and is involved in normal inflammatory and immune responses². Additionally, increased IL-17A plays an important role in the pathogenesis of ankylosing spondylitis (AS), a chronic autoimmune inflammatory disease that primarily affects the axial skeleton², and in the progression of psoriatic arthritis¹.

Secukinumab is a fully humanized monoclonal antibody that binds selectively to IL-17A and inhibits its interaction with the IL-17 receptor, thereby inhibiting the release of proinflammatory cytokines and chemokines². Secukinumab was developed as an IL-17A inhibitor for the treatment of AS and has been approved for the treatment of AS, plaque psoriasis, and psoriatic arthritis. In AS, the levels of a variety of biomarkers (CRP, S100A8, and S100A9) decrease with secukinumab treatment along with symptoms.

Secukinumab was generated in transgenic mice engineered to express the human IgG/κ repertoire in lieu of the murine immunoglobulin repertoire using recombinant human IL-17 as immunogen³. Murine hybridoma cells were obtained that secrete the human IgG/κ antibody and selection for activity against IL-17A was performed.

Secukinumab may have significant cross-reactivity with IL-17F, depending on the chosen experimental conditions⁵.

IL-17A is expressed by Th17 cells, mast cells, and neutrophils.

Il-17R

1 Aboobacker S, Kurn H, Al Aboud AM. Secukinumab. [Updated 2023 Jun 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537091/
2 Blair HA. Drugs. 79(4):433-443. 2019.
3 Patent US7807155B2. https://patents.google.com/patent/US7807155B2/en
4 Elain G, Jeanneau K, Rutkowska A, et al. Glia. 62(5):725-735. 2014.
5 Beerli RR, Bauer M, Fritzer A, et al. MAbs. 6(6):1608-1620. 2014.